There is a general acceptance that European patent law is complicated, particularly in the area of pharmaceutical inventions. Claire Baldock looks at how the EPO approaches these inventions and the positives and negatives for the pharmaceutical industry.
The European Patent Office’s (EPO) approach to granting patents and how it goes about doing this have a large influence on the health of the pharmaceutical sector. The competitiveness and worth of innovative pharmaceuticals are linked to the strength of its patents.
Bringing new and potentially life-saving drugs to the public requires huge investment and there is constant pressure on companies to innovate and produce results in both a timely and a profitable manner. Patents are essential to the process and so the industry is always looking to patent offices to examine and grant patents in a consistent way while being supportive of its needs.
To continue reading, you need a subscription to WIPR. Start a subscription to WIPR for £455.
In-house feature articles, the archive and expert comment require a paid subscription. Subscribe now.
Want to give it a try? We are offering a two week free trial to the WIPR website – register and select “Free Trial” to begin access to the full WIPR archive and read the latest news, features and expert comment. Begin your free trial here.
Is your 2 week free trial about to end? Upgrade to a 12 month subscription for £455 now.
If you have already subscribed please login.
If you have any technical issues please email tech support.
EPO, European Patent Law, pharmaceuticals